Biotech award-winner in search of new capital
The biotech company Immudex, which - among other things - works on a more reliable borrelia-test than the one currently on the market, is already attempting to secure fresh capital to launch new development projects. But the apparent strategy of the company is still to ensure its continued operation and not to bet everything on development projects – and investors like this approach, says company founder and CEO Henrik Pedersen.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app